We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
- Authors
Chen, Shuaiqi; Sun, Guangyu; Chen, Xiaoxu; Salgado, Tiyara; Wu, Shangrong; Hu, Hailong; Liu, Ranlu; Qie, Yunkai
- Abstract
Objective: To explore if switching intravesical chemotherapeutic agents is beneficial in short-term recurrences of high-risk non-muscle-invasive bladder cancer (NMIBC) following the failure of preceding intravesical therapy. Materials and methods: From June 2010 to October 2015, 205 patients with NMIBC who experienced tumor recurrence within a year after receiving first-line intravesical chemotherapy (IVC) were classified into two groups. After a second complete transurethral resection (TUR) process, we immediately altered the intravesical instillation agent for 107 patients (group A). In contrast, the remaining 98 patients (group B) continued using their original intravesical instillation agent. After transurethral resection of the bladder tumor (TURBT), all patients received either an immediate instillation of epirubicin (EPI), gemcitabine (GEM), or hydroxycamptothecin (HCPT), followed by regular induction and maintenance instillations. Recurrence and progression rates were evaluated using the Chi-square test, and recurrence-free survival (RFS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method. Results: In this study, there was no significant difference in either the 5-year tumor recurrence or progression rates between the two groups (p > 0.05) The Kaplan–Meier plot showed no difference in progression-free or recurrence-free survival between the two groups. Conclusion: Switching IVC agents does not improve RFS and PFS for patients with short-term recurrent high-risk NMIBC.
- Subjects
BLADDER cancer; TRANSURETHRAL resection of bladder; NON-muscle invasive bladder cancer; INTRAVESICAL administration; CANCER chemotherapy; PROGRESSION-free survival
- Publication
BMC Urology, 2024, Vol 24, Issue 1, p1
- ISSN
1471-2490
- Publication type
Article
- DOI
10.1186/s12894-024-01410-1